Experimental Therapies: Hepatocyte Transplantation, Gene Therapy, and Liver Assist Devices

Textbook of Gastroenterology, Fifth Edition

Volumn 2, Issue , 2009, Pages 2432-2448

  Roy Chowdhury, Jayanta ^a   Roy Chowdhury, Namita ^a   Horslen, Simon P ^b,c   Fox, Ira J ^d  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Extracorporeal liver assist devices; Hepatocyte transplantation; Hepatocyte transplantation in patients with inherited metabolic disorders; Liver directed gene therapy; Nonviral vectors; Treatment of chronic liver failure

Indexed keywords

EID: 84889959097     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444303254.ch96     Document Type: Chapter

References (163)

1. Moshage HJ, Rijntjes PJ, Hafkenscheid JC, et al. Primary culture of cryopreserved adult human hepatocytes on homologous extracellular matrix and the influence of monocytic products on albumin synthesis. J Hepatol 1988; 7: 34.
2. Demetriou A, Levenson SM, Whiting J, et al. Replacement of hepatic functions in rats by transplantation of microcarrier-attached hepatocytes. Science 1986; 233: 1190.
3. Demetriou A, Levenson SW, Whiting J, et al. Organization, morphology and function of microcarrier-attached transplanted hepatocytes in rats. Proc Natl Acad Sci U S A 1986; 83: 7475.
4. Gupta S, Aragona E, Vemuru RP, et al. Permanent engraftment and function of hepatocytes delivered to the liver: implications for gene therapy and liver repopulation. Hepatology 1991; 14: 144.
5. Gupta S, Rajvanshi P, Lee C-D. Integration of transplanted hepatocytes in host liver plates demonstrated with dipeptidylpeptidase IV deficient rats. Proc Natl Acad Sci U S A 1995; 92: 5860.
6. Eguchi S, Rozga J, Lebow LT, et al. Treatment of hypercholesterolemia in the Watanabe rabbit using allogeneic hepatocellular transplantation under a regeneration stimulus. Transplantation 1996; 62: 588.
7. Irani AN, Malhi H, Slehria S, et al. Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans Cinnamon rats modeling Wilson's disease. Mol Ther 2001; 3: 302.
8. De Vree JM, Ottenhoff R, Bosma PJ, et al. Correction of liver disease by hepatocyte transplantation in a mouse model of progressive familial intrahepatic cholestasis. Gastroenterology 2000; 119: 1720.
9. Michel JL, Rabier D, Rambaud C, et al. [Intrasplenic transplantation of hepatocytes in spf-ash mice with congenital ornithine transcarbamylase deficiency]. Chirurgie 1993; 119: 666.
10. Guha C, Yamanouchi K, Jiang J, et al. Feasibility of hepatocyte transplantation-based therapies for primary hyperoxalurias. Am J Nephrol 2005; 25: 161.
11. Kocken JM, Borel Rinkes IH, Bijma AM, et al. Correction of an inborn error of metabolism by intraportal hepatocyte transplantation in a dog model. Transplantation 1996; 62: 358.
12. Rozga J, Holzman M, Moscioni AD, et al. Repeated intraportal hepatocyte transplantation in analbuminemic rats. Cell Transplant 1995; 4: 237.
13. Overturf K, Al-Dhalimy M, Ou C, et al. Serial transplantation reveals the stem-cell-like regenerative potential of adult mouse hepatocytes. Am J Pathol 1997; 151: 1273.
14. Takahashi M, Deb NJ, Kawashita Y, et al. A novel strategy for in vivo expansion of transplanted hepatocytes using preparative hepatic irradiation and FasL-induced hepatocellular apoptosis. Gene Ther 2003; 10: 304.
15. Oren R, Dabeva MD, Karnezis AN, et al. Role of thyroid hormones in stimulating liver repopulation in the rat by transplanted hepatocytes. Hepatology 1999; 30: 903.
16. Laconi E, Oren R, Mukhopadhyay DK, et al. Long-term, near-total liver replacement by transplantation of isolated hepatocytes in rats treated with retrorsine. Am J Pathol 1998; 153: 319.
17. Guha C, Parashar B, Deb NJ, et al. Liver irradiation: a potential preparative regimen for hepatocyte transplantation. Int J Radiat Oncol Biol Phys 2001; 49: 451.
18. Guha C, Sharma A, Gupta S, et al. Amelioration of radiation induced liver damage in partially hepatectomized rats by hepatocyte transplantation. Cancer Res 1999; 59: 5871.
19. Horslen SP, McCowan TC, Goertzen TC, et al. Isolated hepatocyte transplantation in an infant with a severe urea cycle disorder. Pediatrics 2003; 111: 1262.
20. Reyes J, Rubenstein WS, Mieles L, et al. The use of cultured hepatocyte infusion via the portal vein for the treatment of ornithine transcarbamylase deficiency by transplantation of enzymatically competent ABO/Rh-matched cells. Hepatology 1996; 24: 308A.
21. Strom SC, Chowdhury JR, Fox IJ. Hepatocyte transplantation for the treatment of human disease. Semin Liver Dis 1999; 19: 39.
22. Muraca M, Gerunda G, Neri D, et al. Hepatocyte transplantation as a treatment for glycogen storage disease type 1a. Lancet 2002; 359(9303): 317.
23. Sokal EM, Smets F, Bourgois A, et al. Hepatocyte transplantation in a 4-year-old girl with peroxisomal biogenesis disease: technique, safety, and metabolic follow-up. Transplantation 2003; 76: 735.
24. Dhawan A, Mitry RR, Hughes RD, et al. Hepatocyte transplantation for inherited factor VII deficiency. Transplantation 2004; 78: 1812.
25. Horslen SP, Fox IJ. Hepatocyte transplantation. Transplantation 2004; 77: 1481.
26. Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med 1998; 338: 1422.
27. Chowdhury JR, Strom SC, Chowdhury NR, et al. Hepatocyte transplantation in humans: gene therapy and more. Pediatrics 1998; 102: 647.
28. Makowka L, Rotstein LE, Falk RE, et al. Reversal of toxic and anoxic induced hepatic failure by syngeneic, allogeneic, and xenogeneic hepatocyte transplantation. Surgery 1980; 88: 244.
29. Demetriou AA, Reisner A, Sanchez J, et al. Transplantation of microcarrier-attached hepatocytes into 90% partially hepatectomized rats. Hepatology 1988; 8: 1006.
30. Arkadopoulos N, Chen SC, Khalili TM, et al. Transplantation of hepatocytes for prevention of intracranial hypertension in pigs with ischemic liver failure. Cell Transplant 1998; 7: 357.
31. Habibullah C, Syed I, Qamar A, Taher UZ. Human fetal cell transplantation in patients with fulminant hepatic failure. Transplantation 1994; 58: 951.
32. Strom SC, Fisher AC, Thompson MT, et al. Hepatocyte transplantation as a bridge to orthotopic liver transplantation in terminal liver failure. Transplantation 1997; 63: 559.
33. Bilir B, Guinette D, Karrer F, et al. Hepatocyte transplantation in acute liver failure. Liver Transpl 2000; 6: 32, 41.
34. Soriano HE, Wood RP. Kang DC, et al. Hepatocellular transplantation (HCT) in children with fulminant liver failure (FLF). Hepatology 1997; 26: 239A(443).
35. Strom S, Roy Chowdhury J, Fox I. Hepatocyte transplantation for the treatment of clinical disese. Semin Liver Dis 1999; 19: 39.
36. Miyazaki M, Makowka L, Falk RE, et al. Reversal of lethal, chemotherapeutically induced acute hepatic necrosis in rats by regenerating liver cytosol. Surgery 1983; 94: 142.
37. Braun K, Degen J, Sandgren E. Hepatocyte transplantation in a model of toxin-induced liver disease: variable therapeutic effect during replacement of damaged parenchyma by donor cells. Nat Med 2000; 6: 320.
38. Ribeiro J, Nordlinger B, Ballet F, et al. Intrasplenic hepatocellular transplantation corrects hepatic encephalopathy in portacavalshunted rats. Hepatology 1992; 15: 12.
39. Schumacher IK, Okamoto T, Kim BH, et al. Transplantation of conditionally immortalized hepatocytes to treat hepatic encephalopathy. Hepatology 1996; 24: 337.
40. Kobayashi N, Ito M, Nakamura J, et al. Hepatocyte transplantation in rats with decompensated cirrhosis. Hepatology 2000; 31: 851.
41. Gagandeep S, Rajvanshi P, Sokhi RP, et al. Transplanted hepatocytes engraft, survive, and proliferate in the liver of rats with carbon tetrachloride-induced cirrhosis. J Pathol 2000; 191: 78.
42. Mito M, Kusano M. Hepatocyte transplantation in man. Cell Transplant 1993; 2: 65.
43. Mito M, Kusano M, Ohnishi T, et al. Hepatocellular transplantation. Gastroenterol Jpn 1978; 13: 480.
44. David P, Alexandre E, Audet M, et al. Engraftment and albumin production of intrasplenically transplanted rat hepatocytes (Sprague-Dawley), freshly isolated versus cryopreserved, into Nagase analbuminemic rats (NAR). Cell Transplant 2001; 10: 67.
45. Runge D, Michalopoulos G, Strom S, Runge D. Recent advances in human hepatocyte culture systems. Biochem Biophys Res Com-mun 2000; 274; 1.
46. Tada K, Roy-Chowdhury N, Prasad V, et al. Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes. Cell Transplant 1998; 7: 607.
47. Platt JL, Vercellotti GM, Dalmasso AP, et al. Transplantation of discordant xenografts: a review of progress. Immunol Today 1990; 11: 450.
48. Gunsalus JR, Brady DA, Coulter SM, et al. Reduction of serum cholesterol in Watanabe rabbits by xenogeneic hepatocellular transplantation. Nat Med 1997; 3: 48.
49. Kanazawa A, Platt J. Prospects for xenotransplantation of the liver. Semin Liver Dis 2000; 20: 511.
50. Platt J. New directions for organ transplantation. Nature 1998; 392: 11.
51. Landis CS, Yamanouchi K, Zhou H, et al. Noninvasive evaluation of liver repopulation by transplanted hepatocytes using 31P magnetic resonance spectroscopic imaging. Hepatology 2006; 44: 1250.
52. Greeve J, Jona VK, Roy-Chowdhury N, et al. Hepatic gene transfer of the catalytic subunit of the apolipoprotein B mRNA editing enzyme, APOBEC-1, leads to reduction of LDL in normal and Watanabe heritable hyperlipidemic rabbits. J Lipid Res 1996; 37: 2001.
53. Ferber S, Halkin A, Cohen H, et al. Pancreatic and duodenal homeobox gene 1 induces expression of insulin gene in liver and ameliorates streptozotocin-induced hyperglycemia. Nat Med 2000; 6: 568.
54. Ozaki I, Zern MA, Liu S, et al. Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells. J Hepatol 1999; 31: 53.
55. Scaglioni P, Malegari M, Takahashi M, et al. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24: 1010.
56. Roy Chowdhury J. Prospects of liver cell transplantation and liver directed gene therapy. Semin Liver Dis 1999; 19: 1.
57. Kmiec EB, Kren BT, Steer CJ. Targeted gene repair in mammalian cells using chimeric RNA/DNA oligonucleotides. In: Friedman T (ed.). Development of Human Gene Therapy. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1999: 643.
58. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med 1996; 2: 985.
59. Kokoris MS, Sabo P, Adman ET, et al. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant. Gene Ther 1999; 6: 1415.
60. Mohr L, Shankara S, Yoon S-K, et al. Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 2000; 31: 606.
61. Mohr L, Schauer JI, Boutin RH, et al. Targeted gene transfer to hepatocellular carcinoma cells in vitro using a novel monoclonal antibody-based gene delivery. Hepatology 1999; 29: 82.
62. Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J Virol 1999; 73: 5333.
63. Tanaka T, Cao Y, Folkman J, et al. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 1998; 58: 3362.
64. Blezinger P, Wang J, Gondo M, et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nature Biotech 1999; 17: 343.
65. Fakhrai H, Dorigo O, Shawler DL, et al. Eradication of established intracranial rat gliomas by transforming growth factor b antisense gene therapy. Proc Natl Acad Sci U S A 1996; 93: 2909.
66. Kawashita Y, Ohtsuru A, Kaneda Y, et al. Regression of hepatocellular carcinoma in vitro and in vivo by radiosensitizing suicide gene therapy under the inducible and spatial control of radiation. Hum Gene Ther 1999; 10: 1509.
67. Encke J, zu Pulitz J, Geissler M, et al. Genetic immunization generates cellular and humoral immune responses against the nonstructural proteins of the hepatitis C virus in a murine model. J Immunol 1998; 161: 4917.
68. zu Putlitz J, Skerra A, Wands JR. Intracellular expression of a cloned antibody fragment interferes with hepatitis B virus surface antigen secretion. Biochem Biophys Res Comm 1999; 255: 785.
69. Scaglioni P, Malegari M, Takahashi M, et al. Use of dominant negative mutants of the hepadnaviral core protein as antiviral agents. Hepatology 1996; 24: 1010.
70. Verma IM, Somia N. Gene therapy -promises, problems and prospects. Nature 1997; 389: 239.
71. Kalpana GV. Retroviral vectors for liver-directed gene therapy. Semin Liver Dis 1999; 19: 27.
72. Nguyen TH, Birraux J, Wildhaber B, et al. Ex vivo lentivirus transduction and immediate transplantation of uncultured hepatocytes for treating hyperbilirubinemic Gunn rat. Transplantation 2006; 82: 794.
73. Takahashi M, Ilan Y, Sengupta K, et al. Induction of tolerance to recombinant adenoviruses by injection into newborn rats: long term amelioration of hyperbilirubinemia in Gunn rats. J Biol Chem 1996; 271: 26536.
74. Horwitz MS. Adenoviruses. In: Fields BN, Knipe DM (eds). Virology. New York: Raven Press, 2001: 2301.
75. Yang Y, Li Q, Ertl HCJ, et al. Cellular and humoral immune responses to viral antigen create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 67: 2004.
76. Ghosh SS, Takahaski M, Thummala NR, et al. Liver-directed gene therapy: promises, problems and prospects at the turn of the century. J Hepatology 2000; 32(suppl 1): 238.
77. Kay MA, Meuse L, Gown AM, et al. Transient immunomodulation with anti-CD40 ligand antibody and CTLA4Ig enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver. Proc Natl Acad Sci U S A 1997; 94: 4686.
78. Thummala NR, Ghosh SS, Lee SW, et al. A non-immunogenic adenoviral vector, coexpressing CTLA4Ig and bilirubin-uridine diphosphoglucuronate-glucuronosyltransferase permits long-term, repeatable transgene expression in the Gunn rat model of Crigler-Najjar syndrome. Gene Ther, 2002; 9: 981.
79. Ilan Y, Attavar P, Takahashi M, et al. Induction of central tolerance by intrathymic inoculation of adenoviral antigens into the host thymus permits long term gene therapy in Gunn rats. J Clin Invest 1996; 98: 2640.
80. Ilan Y, Prakash R, Davidson A, et al. Oral tolerization to adenoviral antigens permits long term gene expression using recombinant adenoviral vectors. J Clin Invest 1997; 99: 1098.
81. Fung Y, Federoff HG, Brownlee M, et al. Rapid and efficient gene transfer in human hepatocytes by herpes viral vectors. Hepatology 1995; 22: 723.
82. Hoffmann C, Sandig V, Jennings G. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A 1995; 92: 10099.
83. Walz C, Schlehofer JR, Flentje M, et al. Adeno-associated virus sensitizes HeLa cell tumors to gamma rays. J Virol 1992; 66: 5651.
84. Samulski RJ, Zhu X, Xiao X, et al. Targeted integration of adenoassociated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941.
85. Samulski RJ, Berns KI, Tan M, Muzyczka N. Cloning of adenoassociated virus into pBR322: rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci U S A 1982; 79: 2077.
86. Flotte TR. Adeno-associated virus-mediated gene transfer for lung diseases. Hum Gene Ther 2005; 16: 643.
87. Song S, Laipis PJ, Berns KI, Flotte TR. Effect of DNA-dependent protein kinase on the molecular fate of the rAAV2 genome in skeletal muscle. Proc Natl Acad Sci U S A 2001; 98: 4084.
88. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in hemophilia B patients treated with an AAV vector. Nat Gen 2000; 24: 257.
89. Wang L, Nichols TC, Read MS, et al. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther 2000; 1: 154.
90. Alexander IE, Russell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adenoassociated virus vectors. J Virol 1994; 68: 8282.
91. Gao G, Lu Y, Calcedo R, et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77.
92. Yu JH, Schaffer DV. Advanced targeting strategies for murine retro-viral and adeno-associated viral vectors. In: Schaffer DV, Zhou W (eds). Gene Therapy and Gene Delivery Systems. Springer Press. Germany. 2005: 147.
93. Chao H, Sun L, Bruce A, et al. Expression of human factor VIII by splicing between dimerized AAV vectors. Mol Ther 2002; 5: 716.
94. Strayer DS, Zern MA. Gene delivery to the liver using simian virus 40-derived vectors. Semin Liver Dis 1999; 19: 71.
95. Sauter BV, Parashar B, Roy Chowdhury N, et al. A replication deficient rSV40 mediates liver-directed gene transfer and a long-term amelioration of jaundice in Gunn rats. Gastroenterology 2000; 119: 1348.
96. Zabner J, Fasbender AJ, Moninger T, et al. Cellular and molecular barriers to gene transfer by a cationic lipid. J Biol Chem 1995; 270: 18997.
97. Findeis MA, Wu CH, Wu GY. Ligand-based carrier systems for delivery of DNA to hepatocytes. Methods Enzymol 1994; 247: 341.
98. Kren BT, Bandyopadhyay P, Chowdhury NR, et al. Oligonucleotidemediated site-directed gene repair. Methods Enzymol 2002; 346: 14.
99. Zanta MA, Belguise-Valladier P, Behr J-P. Gene delivery: a single nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. Proc Natl Acad Sci U S A 1998; 96: 91.
100. Sakamoto N, Wu CH, Wu GY. Intracellular cleavage of hepatitis C virus RNA and inhibition of viral protein translation by hammerhead ribozymes. J Clin Invest 1996; 98: 2720.
101. Welch PJ, Tritz R, Yei S, et al. Intracellular application of hairpin ribozyme genes against hepatitis B virus. Gene Ther 1997; 4: 736.
102. Welch PJ, Yei S, Barber JR. Ribozyme gene therapy for hepatitis C virus infection. Clin Diag Virol 1998; 10: 163.
103. Wu CH, Wu GY. Targeted inhibition of hepatitis C virus-directed gene expression in human hepatoma cell lines. Gastroenterology 1998; 114: 1304.
104. Oketani M, Asahina Y, Wu CH, et al. Inhibition of hepatitis C virus-directed gene expression by a DNA ribonuclease. J Hepatol 1999; 31: 628.
105. Paddison PJ, Cleary M, Silva JM, et al. Cloning of short hairpin RNAs for gene knockdown in mammalian cells. Nat Methods 2004; 1: 163.
106. Grimm D, Kay MA. Therapeutic short hairpin RNA expression in the liver: viral targets and vectors. Gene Ther 2006; 13: 563.
107. Xia H, Mao Q, Paulson HL, Davidson BL. siRNA-mediated gene silencing in vitro and in vivo. Nat Biotechnol 2002; 20: 1006.
108. Sun D, Melegari M, Sridhar S, et al. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques 2006; 41: 59.
109. Aravind L, Walker DR, Koonin EV. Conserved domains in DNA repair proteins and evolution of repair systems. Nucleic Acids Res 1999; 27: 1223.
110. Yanez RJ, Porter ACG. Therapeautic gene targeting. Gene Ther 1998; 5: 149.
111. Yamamoto A, Taki T, Yagi H, et al. Cell cycle-dependent expression of the mouse Rad51 gene in proliferating cells. Mol Gen Genet 1996; 251: 1.
112. Chan PP, Glazer PM. Triplex DNA: fundamentals, advances, and potential applications for gene therapy. J Mol Med 1997; 75: 267.
113. Faruqi AF, Datta HJ, Carroll D, et al. Triple-helix formation induces recombination in mammalian cells via a nucleotide excision repair-dependent pathway. Mol Cell Biol 2000; 20: 990.
114. Culver KW, Hsieh W-T, Huyen Y, et al. Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides. Nat Biotechnol 1999; 17: 989.
115. Kren BT, Metz R, Kumar R, et al. Gene repair using RNA/DNA oligonucleotides. Semin Liver Dis 1999; 19: 93.
116. Stürzbecher H-W, Donzelmann B, Henning W, et al. p53 is linked directly to homologous recombination processes via RAD51/RecA protein interaction. EMBO J 1996; 15: 1992.
117. Kren BT, Bandyopadhyay P, Steer CJ. In vivo site-directed mutagenesis of the factor IX gene by chimeric RNA/DNA oligonucleotides. Nat Med 1998; 4: 285.
118. Kren BT, Parashar B, Bandyopadhyay P, et al. Correction of the UDP-glucuronosyl-transferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide. Proc Natl Acad Sci U S A 1999; 96: 10349.
119. Tagalakis AD, Graham IR, Riddell DR, et al. Gene correction of the apolipoprotein (Apo) E2 phenotype to wild-type ApoE3 by in situ chimeroplasty. J Biol Chem 2001; 276: 13226.
120. Lai L-W, Chau B, Lien Y-H. In vivo gene targeting in carbonic anhydrous II deficient mice by chimeric RNA/DNA oligonucleotides. Conference Proceedings: 2nd Annual Meeting of the American Society of Gene Therapy. Washington DC: ASGT, 1999: 236a.
121. Alexeev V, Igoucheva O, Domashenko A, et al. Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide. Nat Biotechnol 2000; 18: 43.
122. Radice AD, Bugaj B, Fitch DHA, Emmons SW. Widespread occurrence of TC1 transposon family: TC1-like transposons from teleost fish. Mol Gen Genet 1994; 244: 606.
123. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997; 91: 501.
124. Yant SR, Meuse L, Chiu W, et al. Somatic integration and long-term transgene expression in normal and hemophilic mice using a DNA transposon system. Nat Genet 2000; 25: 35.
125. Sen PK, Bhalerao RA, Parulkar GP, et al. Use of isolated perfused cadaveric liver in the management of hepatic failure. Surgery 1966; 59: 774.
126. Denis J, Opolon P, Nusinovici V, et al. Treatment of encephalopathy during fulminant hepatic failure by haemodialysis with high permeability membrane. Gut 1978; 19: 787.
127. Redeker AG, Yamahiro HS. Controlled trial of exchange-transfusion therapy in fulminant hepatitis. Lancet 1973; 1(7793): 3.
128. O'Grady JG, Gimson AE, O'Brien CJ, et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186.
129. Barshes NR, Gay AN, Williams B, et al. Support for the acutely failing liver: a comprehensive review of historic and contemporary strategies. J Am Coll Surg 2005; 201: 458.
130. Hughes RD, Pucknell A, Routley D, et al. Evaluation of the BioLogic-DT sorbent-suspension dialyser in patients with fulminant hepatic failure. Int J Artif Organs 1994; 17: 657.
131. Ash SR, Blake DE, Carr DJ, et al. Clinical effects of a sorbent suspension dialysis system in treatment of hepatic coma (the BioLogic-DT). Int J Artif Organs 1992; 15: 151.
132. Mitzner SR, Stange J, Klammt S, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277.
133. Camus C, Lavoue S, Gacouin A, et al. Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 2006; 32: 1817.
134. Montero JL, Pozo JC, Barrera P, et al. Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS). Transplant Proc 2006; 38: 2511.
135. Sen S, Williams R, Jalan R. Emerging indications for albumin dialysis. Am J Gastroenterol 2005; 100: 468.
136. Falkenhagen D, Strobl W, Vogt G, et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999; 23: 81.
137. Santoro A, Faenza S, Mancini E, et al. Prometheus system: a technological support in liver failure. Transplant Proc 2006; 38: 1078.
138. Skwarek A, Grodzicki M, Nyckowski P, et al. The use of Prometheus FPSA system in the treatment of acute liver failure: preliminary results. Transplant Proc 2006; 38: 209.
139. Rifai K, Ernst T, Kretschmer U, et al. Removal selectivity of Prometheus: a new extracorporeal liver support device. World J Gastroenterol 2006; 12: 940.
140. Krisper P, Haditsch B, Stauber R, et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol 2005; 43: 451.
141. Stadlbauer V, Jalan R. Acute liver failure: liver support therapies. Curr Opin Crit Care 2007; 13: 215.
142. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-onchronic alcoholic liver failure. Crit Care 2006; 10: R108.
143. Otto JJ, Pender JC, Cleary JH, et al. The use of a donor liver in experimental animals with elevated blood ammonia. Surgery 1958; 43: 301.
144. Eiseman B, Liem DS, Raffucci F. Heterologous liver perfusion in treatment of hepatic failure. Ann Surg 1965; 162: 329.
145. Stockmann HB, Hiemstra CA, Marquet RL, IJzermans JN. Extra-corporeal perfusion for the treatment of acute liver failure. Ann Surg 2000; 231: 460.
146. Horslen SP, Hammel JM, Fristoe LW, et al. Extracorporeal liver perfusion using human and pig livers for acute liver failure. Transplantation 2000; 70: 1472.
147. Levy MF, Crippin J, Sutton S, et al. Liver allotransplantation after extracorporeal hepatic support with transgenic (hCD55/hCD59) porcine livers: clinical results and lack of pig-to-human transmission of the porcine endogenous retrovirus. Transplantation 2000; 69: 272.
148. Matsumura KN, Guevara GR, Huston H, et al. Hybrid bioartificial liver in hepatic failure: preliminary clinical report. Surgery 1987; 101: 99.
149. Margulis MS, Erukhimov EA, Andreiman LA, Viksna LM. Temporary organ substitution by hemoperfusion through suspension of active donor hepatocytes in a total complex of intensive therapy in patients with acute hepatic insufficiency. Resuscitation 1989; 18: 85.
150. De Bartolo L, Jarosch-Von Schweder G, Haverich A, Bader A. A novel full-scale flat membrane bioreactor utilizing porcine hepatocytes: cell viability and tissue-specific functions. Biotechnol Prog 2000; 16: 102.
151. Gion T, Shimada M, Shirabe K, et al. Evaluation of a hybrid artificial liver using a polyurethane foam packed-Bed culture system in dogs. J Surg Res 1999; 82: 131.
152. Nyberg SL, Peshwa MV, Payne WD, et al. Evolution of the bioartificial liver: the need for randomized clinical trials. Am J Surg 1993; 166: 512.
153. Sussman NL, Gislason GT, Conlin CA, Kelly JH. The Hepatix extra-corporeal liver assist device: initial clinical experience. Artif Organs 1994; 18: 390.
154. Ellis AJ, Hughes RD, Wendon JA, et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446.
155. Rozga J, Williams F, Ro MS, et al. Development of a bioartificial liver: properties and function of a hollow-fiber module inoculated with liver cells. Hepatology 1993; 17: 258.
156. Demetriou AA, Brown RS Jr, Busuttil RW, et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239: 660.
157. Busse B, Gerlach JC. Bioreactors for hybrid liver support: historical aspects and novel designs. Ann N Y Acad Sci 1999; 875: 326.
158. Sauer IM, Kardassis D, Zeillinger K, et al. Clinical extracorporeal hybrid liver support -phase I study with primary porcine liver cells. Xenotransplantation 2003; 10: 460.
159. Sauer IM, Zeilinger K, Obermayer N, et al. Primary human liver cells as source for modular extracorporeal liver support -a preliminary report. Int J Artif Organs 2002; 25: 1001.
160. Mazariegos GV, Patzer JF 2nd, Lopez RC, et al. First clinical use of a novel bioartificial liver support system (BLSS). Am J Transplant 2002; 2: 260.
161. van de Kerkhove MP, Di Florio E, Scuderi V, et al. Bridging a patient with acute liver failure to liver transplantation by the AMCbioartificial liver. Cell Transplant 2003; 12: 563.
162. Morsiani E, Pazzi P, Puviani AC, et al. Early experiences with a porcine hepatocyte-based bioartificial liver in acute hepatic failure patients. Int J Artif Organs 2002; 25: 192.
163. Ding YT, Qiu YD, Chen Z, et al. The development of a new bioartificial liver and its application in 12 acute liver failure patients. World J Gastroenterol 2003; 9: 829.